Promomed received marketing authorization for Enoparin
Promomed Group's portfolio of drug products in demand to combat the new coronavirus infection and its complications has been replenished with a new drug Enoparin (enoxaparin sodium).
On August 13, 2021, the Russian Ministry of Health issued the marketing authorization certificate for Enoparin (enoxaparin sodium) solution for injection in various dosages.
«Already in the first months of the pandemic, Promomed Group developed and released the direct-acting antiviral product Areplivir, since then we have been working systematically and with concentration on expanding the anti-COVID portfolio, conducting relevant research and developing the manufacturing base. As we study the new virus, its effect on the body, its complications and long-term health sequelae, the line of Promomed's drugs in demand for combating the disease is also expanding. Today it includes medicines for the treatment of COVID-19 itself, modern antibiotics, some other drugs, and now the effective anticoagulant Enoparin,» commented Petr Bely, Chairman of the Board of Directors of Promomed Group.
The finished dosage form of Enoparin and the substance for this drug is manufactured at the Biokhimik plant, which is member of the Promomed Group. The main active ingredient, enoxaparin sodium, is isolated from the raw materials of low molecular weight heparins using modern biotechnological methods of purification and sterilization.
In the near future, in partnership with the Mendeleev Engineering Center, Promomed will complete the development of technology for obtaining low-molecular heparins from raw materials of domestic origin and start their production; this means that the production will be fully localized.
Enoxaparin sodium is an effective anticoagulant recommended by the Russian Ministry of Health to prevent a common complications of coronavirus infection – thrombosis and thromboembolism. It is used for the prevention and treatment of deep vein thrombosis, prevention of ischemic complications of unstable angina and myocardial infarction.
